Tonya’s trends: ‘off the shoulder’ – a low-slung look on the up
Author: Tonya WalkerPublished: 11 August 2016
Prep: Cook: Serves:
In the first of a new monthly series, Tonya Walker, the shoe-loving fashionista behind ‘The Shoe Maven’ blog, reveals one of her style secrets – the ‘off the shoulder’ look. Here, she shares why it’s a firm favourite in her wardrobe and she’s sure it will be in yours too
Most people I know with Parkinson’s, including myself, want to be as comfortable as possible in managing daily life with the disease. I’m a big fan of comfortable clothes, but they’re not always stylish. Fortunately, this season’s ‘off the shoulder’ trend offers comfort without sacrificing style.
Whether it be a dress or a top, the ‘off the shoulder’ is easier to put on. I don’t know about you, but sometimes I struggle with putting on and taking off certain tops. But not with an ‘off the shoulder’ top. The neckline is elastic so it easily stretches with your body. The tops are also loose-fitting which allows more room. As for an ‘off the shoulder’ dress, you can just step in and pull it up.
“Even if you don’t think this look is for you, I recommend you give it a try – you might just be pleasantly surprised”
An added benefit of this style is that it covers the scar from my deep brain stimulation (DBS) surgeries and it also covers the battery in my chest.
The trend is popular among many different age groups. Even if you don’t think this look is for you, I recommend you give it a try – you might just be pleasantly surprised. These are a few of my favourite looks that I hesitated to even try on but quickly came to love.
‘The Shoe Maven’
Tonya Walker has been living with Parkinson’s disease since the age of 32 and had DBS surgery on her left side in 2013 and her right in 2015. She created ‘The Shoe Maven’ fashion blog and in 2015 started up her own fashion label called TSM Originals in aid of The Michael J Fox Foundation. She is a passionate advocate for increased awareness of young-onset Parkinson’s and loves shoes. She lives in Florida, US, with her husband and young son, where she is also a law professor.
Meet Andy Butler, the man behind the Parkinson’s People Facebook group
One of Facebook’s largest independent Parkinson’s groups
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.